We want to do more for people living with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases and their families. We want to partner with individuals and companies who share our passion for bringing innovative ideas and solutions to the neurodegenerative disease community. In working together, we can leverage our strengths, assets and relationships to make an impact on the lives of those who need it most.
Interested? Let’s talk.
We’d love to hear about your work and to consider the various ways in which we partner together. Submit your information in the link below and a member of our team will reach out for further discussion.

Featured Publications
Muscle & Nerve
October 2020
Data from the CENTAUR trial published in Muscle & Nerve demonstrates that the administration of AMX0035 results in longer survival for people living with ALS compared to placebo.
The New England Journal of Medicine
September 2020
As published in the New England Journal of Medicine (NEJM), pivotal the CENTAUR trial met its prespecified primary outcome, showing a clinically meaningful and statistically significant benefit on the Revised ALS Functional Rating Scale (ALSFRS-R) — representing a major milestone for the ALS community. Participants experienced similar rates of adverse events in the AMX0035 and placebo groups; however GI events occurred with greater frequency (≥2%) in the AMX0035 group.